Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Cheng-Ling Lee, Hann-Chorng Kuo, Cheng-Ling Lee, Hann-Chorng Kuo

Abstract

Intravesical onabotulinumtoxinA (BoNT-A) injection can relieve symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS), but lacks sustainability. Repeated injections have been shown to provide a superior outcome to a single injection, but data on long-term efficacy and safety is limited. In this prospective study, we enrolled patients with refractory IC/BPS, and treated them with 100 U of BoNT-A injection plus hydrodistention followed by repeated injections every six months for up to two years or until the patient wished to discontinue. A "top-up" dose was offered after the fourth injection. Of these 104 participants, 56.7% completed four BoNT-A injections and 34% voluntarily received the fifth injection due to exacerbated IC symptoms. With a follow-up period of up to 79 months, O'Leary-Sant symptom and problem indexes (ICSI, ICPI, OSS), pain visual analogue scale (VAS) functional bladder capacity, frequency episodes, and global response assessment (GRA) all showed significant improvement (p < 0.0001). Those who received repeated injections had a better success rate during the long-term follow-up period. The incidence of adverse events did not rise with the increasing number of BoNT-A injections. A higher pre-treatment ICSI and ICPI score was predictive for successful response to repeated intravesical BoNT-A injections plus hydrodistention.

Keywords: follow-up; interstitial cystitis/bladder pain syndrome; onabotulinumtoxinA.

Figures

Figure 1
Figure 1
Documented adverse events in each treatment time point.
Figure 2
Figure 2
The cumulative success rate of the patients who received one to four BoNT-A injections.

References

    1. Homma Y., Ueda T., Tomoe H., Lin A.T., Kuo H.C., Lee M.H., Lee J.G., Kim D.Y., Lee K.S. Interstitial cystitis guideline committee. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int. J. Urol. 2009;16:597–615. doi: 10.1111/j.1442-2042.2009.02326.x.
    1. Hanno P.M., Sant G.R. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001;57:2–6. doi: 10.1016/S0090-4295(01)01112-8.
    1. Engelhardt P.F., Morakis N., Daha L.K., Esterbauer B., Riedl C.R. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int. Urogynecol. J. 2011;22:401–405. doi: 10.1007/s00192-010-1294-y.
    1. Wheerler A., Smith H.S. Botulinum toxins: Mechanisms of action, antinocinociception and clinical applications. Toxicology. 2013;306:124–146. doi: 10.1016/j.tox.2013.02.006.
    1. Benecke R. Clinical relevance of botulinum toxin immunogenicity. Biodrugs. 2012;26:e1–e9. doi: 10.2165/11599840-000000000-00000.
    1. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988;138:919–922.
    1. Neuhaus J., Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat. Rev. Urol. 2012;9:707–720. doi: 10.1038/nrurol.2012.217.
    1. Kuo H.C., Jiang Y.H., Tsai Y.C., Kuo Y.C. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn. 2015 doi: 10.1002/nau.22760.
    1. Hanno P.M., Burks D.A., Clemens J.Q., Dmochowski R.R., Erickson D., FitzGerald M.P., Forrest J.B., Gordon B., Gray M., Mayer R.D., et al. AUA Guidelines for the diagnosis and treatment of IC/BPS. J. Urol. 2011;185:2162–2170. doi: 10.1016/j.juro.2011.03.064.
    1. Giannantoni A., Costantini E., Di Stasi S.M., Tascini M.C., Bini V., Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study. Eur. Urol. 2006;49:704–749. doi: 10.1016/j.eururo.2005.12.002.
    1. Chuang Y.C., Yoshimura N., Huang C.C., Chiang P.H., Chancellor M.R. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J. Urol. 2004;172:1529–1532. doi: 10.1097/01.ju.0000137844.77524.97.
    1. Smith C.P., Radziszewski P., Borkowski A., Boone T.B., Chancellor M.B. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871–875. doi: 10.1016/j.urology.2004.06.073.
    1. Giannantoni A., Mearini E., Del Zingaro M., Proietti S., Porena M. Two-year efficacy and safety of botulinum A toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr. Drug Deliv. 2010;7:1–4. doi: 10.2174/156720110790396463.
    1. Kuo H.C., Chancellor M.B. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657–661. doi: 10.1111/j.1464-410X.2009.08495.x.
    1. Kuo H.C. Repeated Onabotulinumtoxin-A injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16:E15–E23.
    1. Pinto R., Lopes T., Frias B., Silva A., Silva J.A., Silva C.M., Cruz C., Cruz F., Dinis P. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010;58:360–365. doi: 10.1016/j.eururo.2010.02.031.
    1. Yamada T., Mishimura M., Mita H. Increased number of apoptotic cells in bladder of interstitial cystitis patients. World J. Urol. 2007;25:407–413. doi: 10.1007/s00345-007-0174-7.
    1. Shie J.H., Liu H.T., Kuo H.C. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012;79:484.e7–484.e13. doi: 10.1016/j.urology.2011.09.049.
    1. Shie J.H., Liu H.Z., Wang Y.S., Kuo H.C. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int. 2013;111:638–646. doi: 10.1111/j.1464-410X.2012.11466.x.
    1. Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol. Urodyn. 2014;33:31–38. doi: 10.1002/nau.22445.
    1. Nonomura N., Takeyama M., Okuyama A. Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: Its association with pain severity and glomerulations. BJU Int. 2009;104:826–831.
    1. Peng C.H., Jhang J.F., Shie J.H., Kuo H.C. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical onabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—Clinical results and immunohistochemistry analysis. Urology. 2013;82:1452.e1–1452.e6.
    1. Kuo H.C. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. Int. J. Clin. Pract. 2013;67:427–434. doi: 10.1111/ijcp.12113.
    1. Gottsch H.P., Miller J.L., Yang C.C., Berger R.E. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol. Urodyn. 2011;30:93–96. doi: 10.1002/nau.20946.
    1. Comperat E., Reitz A., Delcourt A., Capron F., Denys P., Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity: A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur. Urol. 2006;50:1058–1064.
    1. Rohrsted M., Nordsten C., Bagi P. Onabotulinum toxin A (Botox®) in the treatment of neurogenic bladder overactivity. Nephrourol. Mon. 2012;4:437–442. doi: 10.5812/numonthly.1864.
    1. Wu C.Y., Chen I.H., Tong Y.C. Long-term treatment outcomes in patients with interstitial cystitis/painful bladder syndrome: 10-year experience in NCKUH. Urol. Sci. 2013;24:10–13. doi: 10.1016/j.urols.2013.01.005.
    1. Yamada T., Murayama T., Andoh M. Adjuvant hydrodistension under epidural anesthesia for interstitial cystitis. Int. J. Urol. 2003;10:463–468. doi: 10.1046/j.1442-2042.2003.00664.x.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir